You are here: Industry Insights > Alunbrig

News List

Alunbrig scores NICE backing for ALK-positive lung cancer pharmatimes
December 14, 2020
Takeda’s Alunbrig (brigatinib) has been recommended by the UK’s National Institute for Health and Care Excellence (NICE) for patients with ALK-positive advanced non-small cell lung cancer (NSCLC).
US FDA approves Takeda’s ALUNBRIG for rare and serious form of lung cancer pharmaceutical-business-review
May 28, 2020
Takeda Pharmaceutical Company announced that the U.S. Food and Drug Administration (FDA) approved ALUNBRIG (brigatinib) for adult patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) ...
New US approval for Takeda’s Alunbrig pharmatimes
May 26, 2020
US regulators have expanded the scope of Takeda's Alunbrig (brigatinib) to include first-line treatment of adults with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC).
Expanded EU approval for Takeda's Alunbrig pharmatimes
April 10, 2020
European regulators have expanded the scope of Alunbrig (brigatinib) to include its use as a monotherapy for the treatment of adults with anaplastic lymphoma kinase-positive (ALK+) ...
Takeda gets EU approval for ALUNBRIG in ALK+ NSCLC pharmaceutical-business-review
April 09, 2020
Takeda Pharmaceutical has secured expanded approval for ALUNBRIG (brigatinib) in the European Union (EU) to use the tyrosine kinase inhibitor for the treatment of a particular lung cancer population.
Expanded EU approval for Takeda's Alunbrig pharmatimes
April 08, 2020
European regulators have expanded the scope of Alunbrig (brigatinib) to include its use as a monotherapy for the treatment of adults with anaplastic lymphoma kinase-positive (ALK+) ...
NICE backs Takeda’s Alunbrig in second-line lung cancer pharmaceutical-technology
February 20, 2019
The UK’s pricing regulator the National Institute of Health and Care Excellence (NICE) has revised its previous rejection of Takeda’s Alunbrig (brigatinib) for adults with anaplastic lymphoma kinase ....
EC Approves Takeda’s ALUNBRIG for ALK+ Non-Small Cell Lung Cancer biospectrumasia
December 03, 2018
“The European Commission’s decision to approve ALUNBRIG for patients with ALK+ NSCLC is a significant advancement for European patients impacted by this life-threatening disease”
European approval for Takeda's Alunbrig in ALK+ advanced non-small cell lung cancer pharmafile
November 29, 2018
Takeda’s Alunbrig (brigatinib) has been granted marketing approval by the European Commission as a monotherapy to treat anaplastic lymphoma kinase-positive (ALK+) advanced non-small
EU green light for Takeda’s Alunbrig pharmatimes
November 28, 2018
Takeda’s Alunbrig has been approved in Europe as a treatment for a specific group of lung cancer patients, but access to the drug in the UK remains uncertain.

Previous page 1 2 Next page